News

Guardant Health, a leader in precision oncology, has announced a strategic partnership with Zephyr AI, a precision medicine company specializing in artificial intelligence, to…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of WINREVAIR™ (sotatercept-csrk) for the…
Read More...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic treatments for rare bleeding and thrombotic disorders, has raised $157 million in a heavily…
Read More...

Lifecore Biomedical, Inc. and PolyPeptide Laboratories, Inc. have announced a collaboration to offer fully integrated development and manufacturing services for peptide-based…
Read More...

GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide…
Read More...

Eli Lilly and Company announced it will acquire Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage biotechnology company pioneering intravitreal gene therapies for eye…
Read More...

Alkermes plc has announced plans to acquire Avadel Pharmaceuticals plc in a $2.1 billion all-cash deal, marking a major strategic move to expand its presence into the fast-growing sleep…
Read More...

Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

GSK plc announced today that the US Food and Drug Administration (FDA) has approved its cancer therapy Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and…
Read More...

Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced a multi-year collaboration with Genentech, part of the Roche Group, to discover and optimize novel…
Read More...

Roche announced positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) in patients…
Read More...

GSK plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new prefilled…
Read More...

Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its novel corneal cross-linking therapy, Epioxa™ (Epioxa™ HD / Epioxa™), marking a major…
Read More...

Roche has announced positive phase III results from its IMvigor011 study, showing that Tecentriq® (atezolizumab) significantly improves survival outcomes in patients with…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

H. Lundbeck A/S and Contera Pharma have announced a strategic research collaboration aimed at developing RNA-based medicines for serious neurological disorders with high unmet medical…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

The Global Fund to Fight AIDS, Tuberculosis and Malaria has welcomed a new £6 million investment from GSK and its HIV specialist company ViiV Healthcare to strengthen community-led…
Read More...

Roche announced positive Phase III results from its evERA Breast Cancer study, showing that the investigational drug giredestrant, when combined with everolimus, significantly improved…
Read More...